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1. Introduction 
Ischemic heart disease (IHD) is one of the main groups within the class of cardiovascular 
diseases (CVD), and IHD is the most common single cause of morbidity and mortality in 
the Western world (Gaziano et al., 2006). According to the American Heart Association 
Statistics Committee one in three individuals has one or more forms of CVD (Rosamond 
et al., 2007).  
The importance of inflammation in the pathogenesis of IHD, such as, acute myocardial 
infarct (AMI) and coronary artery disease (CAD), has long been established. A large body of 
evidence suggests that inflammation plays a key role in CVD, however, the mechanisms in 
the various stages of the pathological process is not completely understood (Carden and 
Granger, 2000). Inflammation is a complex of defensive mechanisms reacting to the entry of 
harmful agents into the organism or cells, in order to eliminate or repair damaged cells or 
tissue and to restore homeostasis. This broad definition indicates that inflammation does not 
only accompany infectious diseases, but also other conditions causing cell, tissue or organ 
damage.  
The identified risk factors for IHD include both lifestyle and biological factors, such as 
smoking, high blood pressure, high cholesterol levels, obesity, and diabetes that all appear 
to exaggerate many of the vascular alterations elicited by ischemia and reperfusion. Diabetes 
and CVD often appear as two sides of a coin: on one side, diabetes has been rated as an 
equivalent of CVD, and conversely, many patients with established CVD suffer from overt 
or incipient diabetes (Ryden et al., 2007). The mortality from AMI is almost increased five-
fold in diabetic patients compared with non-diabetics (Hansen et al., 2007) and diabetes and 
low-grade inflammation is closely related (Flyvbjerg, 2010). Obesity is seen at epidemic 
proportions all over the world, and is a significant risk factor for, and contributing factor to 
increased morbidity and mortality, most importantly from CVD and diabetes (Lavie et al., 
2009a). Likewise, obesity is also associated with low-grade inflammation and CVD (Yudkin 
et al., 1999; Bastard et al., 2006). 
Although the combination of traditional risk factors such as age, gender, lifestyle, 
dyslipidemia, hypertension and diabetes are well established for the prediction of 
cardiovascular mortality (e.g. the Framingham coronary risk score), these algorithms do not 
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adequately differentiate individuals at moderate risk. Indeed, not all patients with CVD will 
have conventional risk factors and not all patients with risk factors will develop CVD (Khot 
et al., 2003). Both biomarkers of early disease and plaque instability have therefore been 
sought, and the development of new markers to diagnose and prevent CVD is an important 
public health goal worldwide. However, a recent report showed that the addition of a multi-
marker score including 10 new markers to conventional risk factors added only a moderate 
increase in the ability to grade the risk in the general population (Wang et al., 2006). 
Several inflammatory biomarkers have been shown to represent important cardiovascular 
risk factors, and this review will primarily focus on the complement system, the acute-phase 
reactant C-reactive protein (CRP), and the antimicrobial peptides: -defensins. Whether 
these inflammatory proteins mediate IHD themselves or solely serve as markers of systemic 
inflammation and cardiovascular risk stratification is still intensely studied. 
2. Inflammation and IHD 
Growing evidence indicates that IHD is a broad syndrome with multiple pathogenetic and 
aetiological components, which may not be the same in all patients. Extensive literature 
supports the role of inflammation in IHD (Mehta and Li, 1999; Ross, 1999). Inflammatory 
cells, inflammatory proteins and inflammatory responses from vascular cells are all reported 
to play crucial roles in various stages of a number of CVD (Carden and Granger, 2000). 
Some of the inflammatory mechanisms of IHD include, among others, endothelial 
dysfunction, oxidative stress and vascular calcification, that all seems to play an important 
role for the development of cardiovascular disease.  
Although timely restoration of blood-flow after a myocardial ischemic event is essential to 
prevent irreversible cellular injury, it is widely recognized that the outcome of tissue injury 
not only depends on the duration of the ischemic event, but also on reperfusion as a critical 
factor (Khalil et al., 2006). Paradoxically, the reperfusion exacerbates severe tissue damage, 
especially after longer periods of ischemia. The intensity of the inflammatory reaction in 
post-ischemic tissue can be so strong that the injury response to reperfusion can be 
manifested in distant organs (Carden and Granger, 2000). 
The ischemia-reperfusion injury (IRI) results in a local and systemic inflammatory response 
characterized by the production of reactive oxygen species (ROS), leucocyte-endothelial cell 
adhesion, complement activation, endothelial leucocyte migration, increased micro-vascular 
permeability and decreased endothelial-dependent relaxation (Carden and Granger, 2000). 
Within minutes of reperfusion ROS are generated (Cannon, 2005), stimulating the release of 
cytokines and expression of adhesion molecules on damaged cells in reperfused tissue. Several 
hours after onset of reperfusion, neutrophils and other inflammatory cells are activated 
(Frangogiannis et al., 2002; Frangogiannis, 2007) and adhere to the damaged cell membranes 
(Zimmerman et al., 1990; Vinten-Johansen, 2004) for further enhancement of the inflammatory 
response. Thus, IRI poses major problems in the clinic, and effective therapies are required. 
3. Inflammatory biomarkers 
Recent research has been focused on identifying biomarkers, which alone or in combination 
with other risk markers could be useful in monitoring the treatment and as prognostic 
markers for future coronary syndromes and cardiac death in patients with IHD.  
www.intechopen.com
 
Inflammatory Biomarkers in Ischemic Heart Disease 45 
In 2001, a National Institute of Health working group defined a biomarker as “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes or pharmacological responses to a therapeutic intervention 
(BiomarkersDefinitionsWorkingGroup, 2001). Biomarkers are traditionally specific proteins 
circulating in the body fluids that become altered as a consequence of disease progression or 
the effect of a therapeutic intervention and can be divided into different categories:  
 Disease-predictive  
 Diagnostic  
 Prognostic  
 Disease-associated 
 Therapeutic efficacy.  
A number of inflammatory biomarkers have been associated with cardiovascular diseases. 
Biomarker measurements can help explain empirical results of clinical trials by relating the 
effects of interventions on molecular and cellular pathways to clinical responses, thus 
providing an opportunity for researchers to gain a mechanistic understanding. 
3.1 The complement system  
The complement system is an innate, cytotoxic host defence that normally functions to 
eliminate pathogens and facilitates the clearance of damaged tissue and apoptotic cells. 
However, excessive activation of the system may lead to uncontrolled tissue damage. The 
relevance of complement activation in myocardial ischemia was already proposed more 
than four decades ago (Hill and Ward, 1971). The inflammatory mechanisms by which 
tissue injury after an AMI occurs has not been fully elucidated, but strong evidence obtained 
from animal models, as well as clinical studies, support the hypothesis of a role for the 
complement system in IHD (Bjerre et al., 2008). 
The complement system is a biochemical cascade, which helps clear pathogens from an 
organism, and is thus one part of a larger immune system. Three pathways of complement 
activation have been identified (Figure 1), known as the classical, the alternative and the 
lectin pathway. The classical pathway is initiated by C1q binding to antibody complexes 
(Cooper, 1985) whereas the alternative pathway is initiated by spontaneous and direct 
activation of C3 (Muller-Eberhard, 1988). The lectin pathway is initiated either through 
ficolin (M-, L- or H-ficolin) (Matsushita et al., 2001; Frederiksen et al., 2005), by pattern 
recognition of N-acetyl-glucosamine-rich polysaccharides or through mannan-binding lectin 
(MBL) binding to certain carbohydrate structures (Ikeda et al., 1987; Thiel et al., 1997; 
Holmskov et al., 2003).  
Activation of the complement system promotes three main biological activities (Walport, 
2001): I) recruitment of inflammatory cells by anaphylatoxins (C3a, C4a, and C5a), leading to 
accumulation of activated polymorph nuclear leukocytes directly involved in tissue 
destruction, II) opsonisation of pathogens for phagocytosis by the generation of C3b, and III) 
lysis of the pathogen by the generation of a membrane attack complex (MAC, C5b-9) 
penetrating the cell membrane. The loss of membrane integrity destroys the ability to 
control the concentration of salt within the cell and the cell is killed due to this osmotic 
instability. MAC formed in the absence of target membranes binds to S-protein, which 
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inhibits the membrane-damaging effect, and creates a stable non-lytic soluble C5b-9 form 
(sMAC, sC5b-9) (Fosbrink et al., 2005). 
 
Fig. 1. The complement system can be activated through three pathways, which merge at the 
cleavage of C3, leading to the effector mechanisms: I. recruitment of inflammatory cells, II. 
opsonisation and III. the generation of the membrane attack complex (MAC, C5b-9) for cell 
lysis. 
3.1.1 Role of complement in endothelial function  
Ischemia and reperfusion are potent activators of the complement system and both clinical 
and experimental studies in different organs have shown local deposition of complement 
(Riedemann and Ward, 2003; Arumugam et al., 2004).  It has traditionally been assumed that 
the liver is the source of complement proteins that participate in these events, but 
complement proteins are produced in several organs of the body, including the heart and 
the endothelium.  
The human heart expresses mRNAs, translated into proteins, for all of the components of 
the classical complement pathway (Yasojima et al., 1998b). This production is up-regulated 
in areas of myocardial infarct, and the classical complement pathway was found to be fully 
activated on injured myocardial tissue. In addition, production of C3 and C9 mRNAs and 
their protein products was significantly increased in isolated rabbit heart after reperfusion 
injury, and the production by heart in this circumstance substantially exceeds that of the 
normal liver (Yasojima et al., 1998a). 
Endothelial cells also represent one of the extrahepatic sources of complement components 
and regulators. Due to the strategic position along the surface of the vessel wall, they may 
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supply both the circulating blood and the extravascular fluids with these proteins. Most of 
the information on the production of complement components by endothelial cells has been 
obtained using human umbilical vein endothelial cells (HUVECs). HUVECs cultured in 
serum free media were reported to synthesize functional C3, C5, C6, C8, and C9 and 
assembling of the MAC complex was found, indicating that C7 was produced as well 
(Johnson and Hetland, 1991). The C7 production was later confirmed (Langeggen et al., 
2000) and a small production of C5, C6, C8, and C9 demonstrated by RT-PCR and Northern 
blot was reported (Langeggen et al., 2001). Activation of the complement cascade leads to 
the formation of the C5b-9 complex on the cell surface that can cause cell death. However, 
when the numbers of C5b-9 molecules are limited on host cell membranes, it can activate 
signalling pathways leading to cell cycle activation and cell survival (Niculescu and Rus, 
2001).  
The reduction in the capacity of the endothelium to maintain the homeostasis leads to the 
development of pathological inflammatory processes and vascular diseases. An intact 
endothelium is a fully biocompatible surface that is not recognized by the complement 
system. However, blood contact with a damaged endothelium will lead to a certain degree 
of activation of the defence system. Complement activation results in the formation of 
several biological active components including C3a, C5a, iC3b, and C5b-9. In addition, to 
stimulate inflammatory response C5a have been reported to induce production of 
chemokines and cytokines (Czermak et al., 1999).  
3.1.2 Mechanism of complement in IHD  
Cardiovascular risk factors (e.g., hypercholesterolemia, hypertension, smoking, diabetes, 
stress) cause oxidative stress that alters the endothelial cell capacity (Esper et al., 2006; 
Kyrou and Tsigos, 2007), and thus dysfunction of the endothelium has been implicated in 
the pathophysiology of different forms of CVD (reviewed by (Endemann and Schiffrin, 
2004)). Human endothelial cells have been shown to generate reactive oxygen intermediates 
in response to hyperglycaemia and lead to dysfunction in type 2 diabetic patients (Bellin et 
al., 2006). Endothelial dysfunction has been shown to have a prognostic value in patients 
with chest pain (Neunteufl et al., 2000) and both C-reactive protein (CRP) and C3a were 
found to be elevated in patients with unstable angina pectoris (Kostner et al., 2006). Elevated 
plasma levels of C3 was independently associated with MI after accounting for traditional 
cardiovascular risk factors and CRP in patients with MI, whereas the association of CRP was 
dependent of C3 (Carter et al., 2009). 
A number of in vitro studies using HUVECs have shown that under anoxic conditions the 
endothelial cells become activators of the complement system. Collard and co-workers 
showed increased MBL, C3, and iC3b deposition after hypoxia/reoxygenation (Collard et 
al., 2000; Collard et al., 2001). MBL deposition was attenuated in the presence of MBL 
ligands indicating the presence of MBL neo-epitopes on the surface of the endothelial cells. 
Apoptotic endothelial cells deposited C1 and C3d, thus activating the complement system 
(Mold and Morris, 2001). Experimental studies in porcine and rabbits reported that 
complement activation attenuates endothelium-dependent relaxation (Stahl et al., 1995; 
Lennon et al., 1996). The role of complement was mediated by the formation of C5b-9, but 
not through the generation of the anaphylatoxin C3a and C5a. 
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Hill et al. were the first to report a role for the complement system after an ischemic event in 
a rat model of AMI (Hill and Ward, 1971). The association between AMI and complement 
activation was later confirmed in baboons showing deposition of complement factors in the 
infarcted tissue (Pinckard et al., 1980; McManus et al., 1983). Later, several studies of 
experimental myocardial I/R showed deposition of complement; C1 (Vakeva et al., 1994), 
MBL and C3 (Walsh et al., 2005), C4, C5 (McManus et al., 1983; Crawford et al., 1988), C6 (Ito 
et al., 1996), and C5b-9 (Vakeva et al., 1994). MBL knock-out (KO) mice were protected from 
heart I/R injury, but when reconstituted with human recombinant MBL, I/R injury similar 
to that in wild type mice was found. Mice deficient in C2 and factor B (C2/B KO) were also 
protected form heart I/R injury but no protection was found in C1q or factor D KO mice 
(Walsh et al., 2005). In a murine model of coronary artery ischemia the involvement of 
natural IgM antibodies has been linked to both the classical and the lectin pathways (Zhang 
et al., 2006a; Zhang et al., 2006b). Mice bearing an altered natural IgM repertoire were 
significantly protected based on the reduced infarct size, limited apoptosis of 
cardiomyocytes, and decreased neutrophil infiltration. 
In addition to direct lytic activity, C5b-9 also directly attenuates endothelium-dependent 
(i.e., NO-mediated) relaxation (Stahl et al., 1995). Furthermore, C5b-9 is found to play a role 
in leucocyte activation, adherence and chemotaxis by induction of different cytokines 
(Kilgore et al., 1996; Vakeva et al., 1998). Also, activation of endothelial NF-kB and the 
stimulation of expression of endothelial adhesion molecules have been observed. 
Furthermore, a role for C5b-9 in mediating myocardial apoptosis after ischemia-reperfusion 
was demonstrated in a model of rat myocardial IRI (Vakeva et al., 1998). We have shown 
that increased complement activity as indicated by MBL and sC5b-9 levels, was associated 
with increased risk of cardiac dysfunction in STEMI patients treated with pPCI (Haahr-
Pedersen et al., 2009). High plasma MBL and low plasma sC5b-9 was independently 
associated with increased risk of cardiac dysfunction, likely due to increased complement 
activity during the ischemic and reperfusion process. The predictive value of low peripheral 
plasma sC5b-9 may be explained by an accumulation and activation of sC5b-9 in the 
infarcted myocardium. Furthermore, an elevated plasma sC5b-9 level was found in patients 
with chronic heart failure due to IHD (Bjerre et al., 2010). In addition, an independent 
association between sC5b-9, insulin resistance and endothelial dysfunction was found, 
which may suggest that insulin resistance leading to endothelial activation results in 
activation of the complement system thus damaging the heart. 
3.1.3 Therapeutic inhibition of complement in IHD  
Based on the studies discussed above, regulation of the complement system seems to be of 
great importance. Indeed, several animal studies point to a possible beneficial role of 
complement depletion in the treatment of post-ischemic MI; reviewed by (Bjerre et al., 2008; 
Diepenhorst et al., 2009). Unfortunately, clinical studies focused on complement depletion in 
humans, especially the use of anti-C5 antibodies, primarily Pexelizumab, have largely been 
disappointing and not proven effective in the setting of CVD, discussed in details elsewhere: 
(Bjerre et al., 2008; Diepenhorst et al., 2009; Banz and Rieben, 2011).  
Although much of the preclinical work and data accumulated in the past years have been 
positive, the problem with complement-mediated damage in IR-injury was not “easy to fix”. 
Thus conclusions drawn from animal studies should be extrapolated to the human settings 
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with caution. It may lie in the fact that complement activation represents only a part of the 
cascade of attack directed against the vasculature. An exaggerated blockade of the immune 
system may increase the susceptibility to infections, thus a well-balanced inhibition of the 
complement activation is required in order to avoid side effects of pharmaceutically induced 
modification of the immune system. Direct targeting may be the key to future treatment 
strategies, including targeting of the complement inhibitor to the site of injury by localized 
intravascular application. 
3.2 C-reactive protein  
C-reactive protein (CRP), an acute-phase reactant mainly produced by hepatocytes in 
response to interleukin (IL) 6, is a nonspecific marker of systemic inflammation, and is the 
most intensively studied inflammatory biomarker in CVD. In addition, a large number of 
reports have shown that CRP may be implicated in the pathogenesis of many chronic 
diseases, including diabetes, cancer and alzheimer dementia, and major CVDs, such as, 
coronary heart disease (CHD), AMI and IHD (Clyne and Olshaker, 1999; Hirschfield and 
Pepys, 2003; Lavie et al., 2009b). Of note, CRP levels has been associated with the size of the 
infarct (de Beer et al., 1982). 
The concentration of CRP increases rapidly; it may raise hundreds-fold after acute tissue 
injury or inflammation, and declines rapidly with resolution of the injurious process. In 
healthy persons, normal CRP levels are generally considered to be < 3 mg/L (Shine et al., 
1981). 
3.2.1 High sensitive CRP and IHD 
In the 1990s, rapid and more precise methods of quantifying CRP was established and CRP 
levels measured as low as 0.04 mg/L were possible, referred to as high sensitive (hs) CRP 
(Jaye and Waites, 1997). Low-grade inflammation is found in IHD, and CRP levels are not as 
increased as compared to other inflammatory conditions. Therefore, a cardiovascular risk 
scale according to hsCRP levels is recommended by the American Heart Association and 
Centers for Disease Control and Prevention (Pearson et al., 2003).  
Individuals with hsCRP levels; 
 <1 mg/L are at lower relative risk for cardiovascular events,  
 1 to 3 mg/L are at intermediate risk,  
 >3 mg/L are at higher relative risk.  
In the Copenhagen City Heart study, investigating more than 10,000 apparently healthy 
participants, elevated hsCRP levels were found to be associated with increased risk of IHD. 
In fact, the risk of IHD was more than doubled (HR=2.2, 1.6-2.9) in individuals with CRP 
levels above 3 mg/L as compared to individuals with CRP levels below 1 mg/L (Zacho et 
al., 2008).  
3.2.2 Possible links between hsCRP and IHD 
Inflammation clearly plays a clinically significant role in the development of CVD. 
Consequently, as a marker of inflammation, hsCRP has been studied extensively in patients 
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with CVD. The predictive value of hsCRP has been widely investigated but the results are 
contradictive. More than 20 large prospective trials have shown that hsCRP is an 
independent predictor of future cardiovascular events (Ridker, 2007). In the most recent 
comprehensive meta-analysis studies of cardiovascular risk factors (more than 50 
prospective studies with over 160,000 participants, none of them with a history of coronary 
heart disease or stroke) (Kaptoge et al., 2010), hsCRP was consistently found to be an 
independent predictor of CVD. However, the association with ischemic vascular disease 
depends considerably on conventional risk factors and other markers of inflammation. A 
critical review by Levinson and colleagues argues that hsCRP is poor discrimination over a 
wide range of values when used in conjunction with risk factors for lipoprotein lipids, 
hypertension, metabolic syndrome, and diabetes (Levinson et al., 2004). Danesh and 
colleagues published a study, performed in a high-risk population with nonfatal myocardial 
infarct, which questioned the role of CRP in the assessment of cardiovascular risk. However, 
hsCRP maintained a predictive value after adjustments for smoking and hypertension 
(Danesh et al., 2004). 
A panel of multiple biomarkers, 10 biomarkers in total including hsCRP, was used for 
prediction of death and major cardiovascular event in more than 3000 participants of the 
Framingham Off-spring study followed for 10 years (Wang et al., 2006). As a single marker, 
hsCRP predicted risk of death but no major cardiovascular events after adjusting for other 
biomarkers, and individuals with high multimarker scores had almost 4 times as great a risk 
of death. Nonetheless, the authors concluded that the use of contemporary biomarkers adds 
only moderately to standard risk factors. In the Women’s Health Study, CRP was found to 
be additive to LDL-cholesterol in predicting future CVD in healthy American women 
(n=28,263 apparently healthy postmenopausal women) (Ridker et al., 2000a). Of the 12 
markers measured (including hsCRP and IL-6), hs-CRP was the strongest uni-variant 
predictor of cardiovascular events, and the only plasma marker predicting risk after 
adjustment in a multi-variant analysis. This was confirmed in a large meta-analysis of 
hsCRP as a single biomarker in patients with stable CAD, but the authors concluded that a 
routine measurement of CRP should not be recommended as a single prognostic biomarker 
(Hemingway et al., 2010). However, in combination with other biomarkers, hsCRP seems to 
add significant information to traditional risk factors for CVD, and the value of adding 
hsCRP to standard risk equations was noted in separate cohorts of asymptomatic (middle-
aged or elderly) men and women (Lavie et al., 2009b).  
In the Caerphilly Prospective Heart Disease Study, Mendall and colleagues, showed a 
significant and positive association between CRP and incidents of IHD, not affected by 
ischemia history (Mendall et al., 2000). However, after adjustment of lifestyle risk factors 
(such as smoking and obesity) only the association with all-cause mortality remained 
significant. Plasma hsCRP was not found as an independent predictor of long-term IHD risk 
in a 13-year-follow-up study of men with no previous history of IHD (n=1982) (St-Pierre et 
al., 2005). The authors thus concluded that neither CRP nor the systemic inflammation 
appeared to have a direct role in the development of IHD. But the association of hsCRP with 
IHD may be that CRP levels are raised non-specifically by a variety of exposures that are 
themselves implicated in the pathogenesis of IHD (Figure 2). 
A connection between CRP and activation of the complement system was proposed more 
than 35 years ago, after the discovery of aggregated or ligand-complexed human CRP was 
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able to bind to C1q and activate the classical pathway (Kaplan and Volanakis, 1974; Siegel et 
al., 1974; Jiang et al., 1991), thus mediating the functions summarized in Figure 1. CRP was 
later found to co-localize with activated complement fragments in atherosclerotic lesions 
(Bhakdi et al., 1999; Yasojima et al., 2001) and CRP-mediated complement activation in the 
arterial wall may be considered as an important pathogenic feature in CVD.  
 
Fig. 2. Schematic depiction of potential mechanisms of CRP involvement in the pathogenesis 
of IHD. 
A number of pro-inflammatory cytokines have been shown to play roles in the process 
leading to IHD, but IL-6, in particular, appears to have a central role, e.g. by stimulating the 
liver to increase the CRP production. However, even with a strong correlation between IL-6 
and CRP, IL-6 was found to predict future AMI in a group of apparently healthy men 
(Ridker et al., 2000b).  
CRP binds to apolipoprotein-containing lipoproteins like LDL (de Beer et al., 1982) and very 
low-density lipoprotein (VLDL) (Rowe et al., 1984), which may be of considerable 
importance in the pathogenesis of CVD. More recent studies revealed that CRP 
preferentially binds to modified forms of LDL; enzymatically modified LDL (Bhakdi et al., 
1999) and oxidized LDL (Chang et al., 2002), and CRP was reported to mediate LDL uptake 
by macrophages (Zwaka et al., 2001). Opsonisation of LDL lead to monocyte infiltration and 
the formation of foam cells resulting in plaque formation and eventually IHD. 
CRP was found to cause expression of cell adhesion molecules with a significant dose-
dependent expression of ICAM-1, VCAM-1 and E-selectin in human umbilical vein 
endothelial cells (HUVEC) following CRP stimulation (Pasceri et al., 2000). Furthermore, 
production of chemokines monocyte chemoattractant protein-1 (MCP-1), which plays an 
important role in recruitment of monocytes into the vessel wall and thus the formation of 
plaques, was directly induced by CRP (Pasceri et al., 2001).  
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3.2.3 Is CRP a potential therapeutic in prevention of IHD?  
As described in the previous section, CRP is reported to be associated with a wide range of 
biomarkers and risk factors of IHD. Thus, overestimating of the true effect of hsCRP on CVD 
risk, because of confounding effects, constitute a challenge. Support for a role of CRP in the 
pathogenesis of CVD comes primary from epidemiologic studies, which in general have 
observed an association between elevated plasma CRP and cardiovascular events.  
Although hsCRP may not be the ideal marker of IHD, it seems to be very reliable, and 
hsCRP is a simple, non-invasive, commercially available, inexpensive and reproducible 
biomarker. CRP measurement has a lot of advantages; the protein is stable and the 
concentration is not subjected to time-of-the day variations (Meier-Ewert et al., 2001). Thus, 
determination of baseline hsCRP for cardiovascular risk prediction may be performed 
without concern for diurnal variation. 
Availability of drugs to block CRP binding and its effects in vivo would provide a powerful 
tool for determining whether CRP is just a marker or does indeed participate in the 
pathogenesis of CVD complications. Griselli and colleagues (Griselli et al., 1999) showed 
that injection of human CRP in a rat model of AMI enhanced the infarct size, of note rat CRP 
does not activate rat complement, whereas human CRP activate both rat and human 
complement. However, in vivo complement depletion, by cobra venom factor, completely 
abrogated this. A similar effect was later found by administration of a specific synthetic 
CRP-inhibitor, 1,6-bis(phosphocholine)-hexane, which reduced the infarct size and thus 
provided promising results for therapeutic inhibition of CRP (Pepys et al., 2006). 
Statins lower the levels of LDL-cholesterol and CRP. Ridker and colleagues showed, in a 
sub-population (n= 3745) derived from the Pravastatin or Atorvastatin Evaluation and 
Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) study, 
that patients with low hsCRP levels after statin treatment had improved cardiovascular 
outcome (Ridker et al., 2005). Patients in whom statin therapy resulted in hsCRP levels 
below 2 mg/L overall had better clinical outcomes regardless of the LDL-cholesterol level 
achieved. Recently, a study JUPITER: Justification for the Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin (n=17802), of healthy individuals without history 
of CVD but hsCRP > 2 mg/L and low LDL concentration, showed beneficial effect of 
Rosuvastatin (Ridker et al., 2007; Kones, 2010; Ridker et al., 2010). The study was terminated 
due to a great risk-reduction in AMI, CVD and death from cardiovascular causes, indicating 
that part of the statin effect may be mediated through lowering CRP.  
Aside from whether measurement of CRP is useful in assessments of CVD, studies are 
needed to help determine if CRP is a mediator or a marker of CVD. Zacho et al. showed that 
genetic variants that are associated with a lifelong increased plasma CRP level are not 
associated with increased risk of IHD (Zacho et al., 2008), indicating CRP as a marker but 
not as an actual contributor. 
3.3 Anti-microbial peptides 
The involvement of polymorphonuclear neutrophils (PMNs) in the pathogenesis of CVD 
has received relatively little attention, despite their presence in the atherosclerotic plaques 
(Quinn et al., 2008). PMN counts have been reported as independent risk factors for 
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cardiovascular outcome (Madjid et al., 2004) and during inflammation PMNs are activated 
in order to enhance the inflammatory response and releases antimicrobial peptides into 
circulation.  
Anti-microbial peptides are polypeptides of fewer than 100 amino acids. The human innate 
immune system includes two main families; defensins and cathelicidins. Defensins, also 
termed human neutrophil peptides (HNP) as they are found in large amounts in 
neutrophils, are secreted during phagocytosis as a first line of defence against invading 
organisms (Ganz, 2003).  
3.3.1 -defensins  
Three different classes of defensin are identified in mammals, two of which are found in 
humans; - and -defensin (Ganz, 1987). The human family of -defensins are composed of 
3 closely related gene products, also referred to as human neutrophil peptides 1-3 (HNPs-1-
3) and HNP4, HNP5 and HNP6. The -defensins are cationic peptides, cysteine-rich 
peptides of approximately 3 kDa and are normally sequestered in the granules of 
neutrophils, where they constitute 5% of the total cellular protein and are involved in the 
intracellular killing of prokaryotic organisms (Ganz, 1987). Under normal conditions, only 
small amounts of -defensins (nanomolar range) are found in plasma. However, during 
inflammatory reactions, -defensins are released extracellularly, which could exert harmful 
effects on host cells. Increased plasma concentrations of -defensins have been described in 
several inflammatory diseases (Ganz, 2003; Klotman and Chang, 2006; de Leeuw and Lu, 
2007).  
3.3.2 Possible link between -defensins and IHD  
The cationic nature of the -defensins prefers the negatively charged phospholipids of the 
bacterial membrane as target and avoids the more neutral charged mammalian cell 
membrane. However, both a direct and an indirect chemoattracting role of -defensins has 
been reported for a number of cells (Oppenheim et al., 2003). In addition, -defensin was 
found to promote oxidative stress and induces endothelial dysfunction by reducing the 
endothelium-dependent relaxation in porcine coronary arteries (Kougias et al., 2006). This 
effect is associated with increased superoxide radical production and decreased eNOS 
expression. Also, -defensins is capable of forming complexes with C1q and MBL, thus 
playing a role in the regulation of both the classical and the lectin pathway of complement 
activation (Groeneveld et al., 2007).  
Localization of -defensins were analysed by the use of immunohistochemical staining of 
coronary arteries from patients with severe CVD or normal donor heart tissue (Barnathan et 
al., 1997). Of interest, -defensin was found most prominently in association with intima 
smooth muscle cells of both normal or atherosclerotic vessels. -defensins has been reported as 
an atherogenic agent by enhancing and promoting stable complexes with LDL particles, thus 
stimulating the binding to endothelial and smooth muscle cells (Higazi et al., 1997). In 
addition, in human cerebral vessels obtained during autopsy, -defensin and LDL co-localized 
primary within the atherosclerotic areas, and the staining intensity correlated with the severity 
of the disease. The authors hypothesize that the small -defensins may rapidly cross the 
endothelial barrier and gain access to sub-endothelial matrix and affording the binding of LDL 
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and a complex relative resistant to degradation. Retention of LDL in the arteries may 
predispose to pro-atherogenic modifications, such as, oxidation and internalization by foam 
cells. In addition, an independent negative relationship between high-density lipoprotein 
(HDL) has later been described (Saraheimo et al., 2008). Furthermore, -defensins were found 
to inhibit the fibrionolytic activity by binding to tissue plasminogen activator molecule 
(Kougias et al., 2005). In a small study of patients undergoing elective coronary artery 
catheterization, an accumulation of -defensin in the human skin was described and the 
accumulated amount correlated with the severity of coronary artery disease (Nassar et al., 
2007). Of note, no correlation between CRP and -defensin was found in this study. 
Chronic low-grade inflammation is a hallmark of obesity and diabetes, and has been 
causally linked to the development of premature CVD. In a group of type-1 diabetic 
patients, with a 10-year-follow-up-period of cardiovascular end-points, elevated baseline 
plasma -defensin levels were an independent predictor for cardiovascular morbidity and 
mortality (Joseph et al., 2008). In a recent study, the risk of cardiovascular mortality was 
significantly increased with elevated plasma -defensin levels in patients admitted for 
elective lower extremity artery surgery (Urbonaviciene et al., 2011). Surprisingly, patients 
with high -defensin levels combined with high hs-CRP levels had a five time increased risk 
of cardiovascular death compared to patients in whom only one or none of the peptides was 
elevated. 
4. Perspectives 
Inflammatory biomarkers may have prognostic value for future cardiovascular risk 
stratification among individuals with high risk or a history of IHD, but they may also in 
particular be useful in apparently healthy individuals who might be at higher risk than 
estimated by the traditional risk factor scores. Using a biomarker profile that covers various 
aspects of the complex pathophysiology of IHD may increase the rational basis for 
cardiovascular risk assessment. As decribed above, a multiple inflammatory role of the 
combination of complement activation, CRP, LDL and -defensins may participate in the 
pathogenesis of IHD and other CVD.  
With the emergence of novel biomarkers for inflammation and vascular damage it may be 
possible to characterize different contributions of each of these major mechanisms to short- 
and long-term prognosis following CVD. Hopefully, patients may benefit from different 
therapeutic strategies depending on their personal biomarker profile in the future. So far, 
however, results about which biomarkers are the most suitable for diagnosis or prognosis of 
IHD remain conflicting, and further research within this field is needed. 
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